HOOK(Delisted)
·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 2
Revenue Beats Expectation
Dark Cloud Cover
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HOOK
Hookipa Pharma Inc.
A company that develops a new class of immunotherapies based on its proprietary arenavirus platform
350 Fifth Avenue, 72nd Floor, Suite 7240, New York, New York 10118
--
HOOKIPA Pharma Inc., incorporated in February 2017 under the laws of the State of Delaware in the name of Hookipa Biotech, Inc., is a wholly-owned subsidiary of Hookipa Biotech AG. The company is a clinical-stage biopharmaceutical company developing novel immunotherapies based on a proprietary arenavirus platform designed to target and amplify T-cell immune responses to fight disease. The company is building a proprietary immuno-oncology pipeline by targeting oncovirus cancer antigens, autoantigens and next-generation antigens. The company's oncology portfolio includes three disclosed programs, HB-200, HB-300 and HB-700, all of which use replication technology.
Company Financials
EPS
HOOK has released its 2024 Q3 earnings. EPS was reported at -1.1, versus the expected -1.9, beating expectations. The chart below visualizes how HOOK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HOOK has released its 2025 Q1 earnings report, with revenue of 2.00M, reflecting a YoY change of -94.52%, and net profit of -15.43M, showing a YoY change of -207.26%. The Sankey diagram below clearly presents HOOK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
